Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fupu cold particles
- Development stage
- Unknown
- Lead developer
- Zhejiang Tianyitang Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fupu cold particles (芙朴感冒颗粒) is a traditional Chinese medicine (TCM) granule formulation developed and manufactured by Zhejiang Tianyitang Pharmaceutical. It is composed of four main active herbal ingredients: hibiscus leaf (*Folium Hibisci mutabilis*), magnolia bark (*Cortex Magnoliae officinalis*), tangerine peel (*Pericarpium Citri reticulatae*), and fried burdock fruit (*Fructus Arctii*). The formulation is indicated for the treatment of wind-heat or wind-heat with dampness common cold, which presents with symptoms such as fever, headache, sore throat, body aches, nasal congestion, and reduced appetite. It functions by clearing heat, detoxifying, dispersing lung qi, relieving sore throat, and regulating qi. Fupu cold particles is approved and marketed in China.
- Brand names
- Fupu
- Other names
- Fupu Ganmao granulesFupu Ganmao Keli芙朴感冒颗粒
02
Targets
CCL2 (C-C motif chemokine 2)IFNG (Interferon gamma)IL1A (Interleukin 1 alpha)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Fupu cold particles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fupu cold particles.